Both Abbott and Medtronic have introduced meaningful ... such as lengthening sensor life, shrinking the size and profile of the CGM, making the insertion less painful, and improving accuracy.

Every study in these AID systems has been done with the DexCom sensor ... pump as well as the CGM system, making it, in my opinion, more user-friendly. So far, Medtronic has a much lower market ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

In August, the company announced that it has entered into a unique global partnership with Medtronic to connect Abbott's FreeStyle Libre CGM sensor with Medtronic’s automated insulin delivery ...

Abbott Laboratories (NYSE:ABT) entered into a global partnership with Medtronic to connect its FreeStyle Libre CGM sensor with automated insulin delivery systems. The company launched several new ...

Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

In August, we announced that we had entered into a unique global partnership with Medtronic to connect Abbott's world-leading FreeStyle Libre CGM sensor with their automated insulin delivery systems.

The global injection pen market is poised for significant growth, with projections indicating a robust compound annual growth rate (CAGR) of 7.0% from 2022 to 2033. The market is expected to escalate ...

England's NHS is testing an artificial pancreas for children with Type 1 diabetes, a device already available in India.

Roche is teaming up with two medical tech companies to develop an automated insulin delivery system, the first steps towards an ‘artificial pancreas.’ The Swiss pharma will work with existing ...